Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2941260 | 0.95 | FDPS (0.41) | FDPSSMPD1 | |
| SCHEMBL2940140 | 0.93 | SMPD1 (0.43) | FDPSSMPD1 | |
| SCHEMBL1903133 | 0.85 | CA2 (0.42) | FDPSCYP3A4L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL3675752 | 0.84 | POLB (0.43) | FDPSCYP3A4L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL3151606 | 0.84 | FDPS (0.38) | FDPSCYP3A4L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL10451891 | 0.82 | CA1 (0.49) | FDPSCYP3A4L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL28817638 | 0.80 | CYP3A4 (0.40) | CYP3A4L3MBTL1CYP2C9CYP2C19CA2 | |
| SCHEMBL3147647 | 0.79 | FDPS (0.40) | FDPSCA1SMPD1 | |
| SCHEMBL13924959 | 0.79 | GPR84 (0.47) | FDPSSMPD1 | |
| SCHEMBL5326687 | 0.79 | GPR84 (0.47) | FDPSSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100111888-A1 | Organic Compounds and Compositions Having the Ability to Modulate Fragrance Compositions | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| EP-2152658-A2 | ORGANIC COMPOUNDS AND COMPOSITIONS HAVING THE ABILITY TO MODULATE FRAGRANCE COMPOSITIONS | Givaudan SA (CH) | 2010-02-17 | — | — | EP | disclosed |
| EP-2139354-A2 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008116339-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116338-A2 | ORGANIC COMPOUNDS AND COMPOSITIONS HAVING THE ABILITY TO MODULATE FRAGRANCE COMPOSITIONS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113460-A1 | Organic Compounds | CYP2B6, CYP2A6, CYP2A13 | FDPS 233/4885CYP3A4 10/4885L3MBTL1 4599/4885 |
| US-20100111888-A1 | Organic Compounds and Compositions Having the Ability to Modulate Fragrance Compositions | CYP2A13, CYP1A1, CYP1B1 | FDPS 239/4885CYP3A4 9/4885L3MBTL1 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.